Day +100 Platelet Count Predicts Survival Post Allogeneic Hematopoietic Stem Cell Transplantation in Children with Hematologic Malignancies

Publication date: Available online 15 January 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Hisham Moneib, Hanafy Hafez, Amr Abdalla, Omneya Hassanain., Leslie Lehmann, Alaa el HaddadAbstractRecovery of platelet count by day 100 post Hematopoietic Stem Cell Transplantation (HSCT) is affected by many factors and has been reported to be a predictor of overall survival in a variety of diseases and donor types. We investigated the correlation between day +100 platelet count and overall survival post allogeneic HSCT in a relatively homogeneous cohort of pediatric patients with hematological malignancies. We conducted a retrospective study of 152 consecutive patients who underwent allogeneic HSCT at the Children’s Cancer Hospital Egypt (CCHE 57357) between 2009 and 2015 with a minimum follow up duration of one year post transplant. All eligible patients received myeloablative conditioning and all had matched related donors. Patients who survived without relapse until day 100 post HSCT were divided into two groups: early platelet recovery (EPR) (platelet count ≥100x109/L at day +100 post transplant) and delayed platelet recovery (DPR) (platelet count <100x109/L at day +100 post transplant). At day+100, 113 patients (74%) had EPR and 39 patients (26%) had DPR. With a median follow-up of 41 months (range 12 - 93 months), 41 patients (27.2%) died, 35 due to relapsed disease. The 3 year disease free survival (DFS) and overall survival (OS) were 68±7.84 % and 71.9...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research